Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardian Pharmacy Services (GRDN) Change in Receivables (2023 - 2025)

Historic Change in Receivables for Guardian Pharmacy Services (GRDN) over the last 3 years, with Q3 2025 value amounting to $13.2 million.

  • Guardian Pharmacy Services' Change in Receivables rose 51761.95% to $13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.8 million, marking a year-over-year increase of 86.63%. This contributed to the annual value of $25.5 million for FY2024, which is 7826.66% up from last year.
  • Per Guardian Pharmacy Services' latest filing, its Change in Receivables stood at $13.2 million for Q3 2025, which was up 51761.95% from -$2.6 million recorded in Q2 2025.
  • In the past 5 years, Guardian Pharmacy Services' Change in Receivables ranged from a high of $13.2 million in Q3 2025 and a low of -$2.6 million during Q2 2025
  • Moreover, its 3-year median value for Change in Receivables was $4.0 million (2023), whereas its average is $4.9 million.
  • Within the past 5 years, the most significant YoY rise in Guardian Pharmacy Services' Change in Receivables was 51761.95% (2025), while the steepest drop was 14624.71% (2025).
  • Guardian Pharmacy Services' Change in Receivables (Quarter) stood at $2.3 million in 2023, then skyrocketed by 250.73% to $8.2 million in 2024, then soared by 60.73% to $13.2 million in 2025.
  • Its Change in Receivables stands at $13.2 million for Q3 2025, versus -$2.6 million for Q2 2025 and $1.0 million for Q1 2025.